"Vasodilator Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to cause dilation of the blood vessels.
| Descriptor ID |
D014665
|
| MeSH Number(s) |
D27.505.954.411.918
|
| Concept/Terms |
Vasodilator Agents- Vasodilator Agents
- Agents, Vasodilator
- Vasodilators
- Vasorelaxants
- Vasodilator Drugs
- Drugs, Vasodilator
|
Below are MeSH descriptors whose meaning is more general than "Vasodilator Agents".
Below are MeSH descriptors whose meaning is more specific than "Vasodilator Agents".
This graph shows the total number of publications written about "Vasodilator Agents" by people in this website by year, and whether "Vasodilator Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 4 | 6 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 4 | 1 | 5 |
| 2002 | 5 | 1 | 6 |
| 2003 | 3 | 2 | 5 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 4 | 2 | 6 |
| 2010 | 1 | 3 | 4 |
| 2011 | 3 | 4 | 7 |
| 2012 | 2 | 3 | 5 |
| 2013 | 2 | 2 | 4 |
| 2014 | 5 | 2 | 7 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 4 | 6 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 2 | 1 | 3 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vasodilator Agents" by people in Profiles.
-
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clin Pharmacol Ther. 2025 12; 118(6):1430-1436.
-
Expression and function of ß-site amyloid precursor protein-cleaving enzyme 2 in vascular endothelium. Am J Physiol Heart Circ Physiol. 2025 08 01; 329(2):H291-H302.
-
Efficacy Assessment of Cerebral Perfusion Augmentation through Functional Connectivity in an Acute Canine Stroke Model. AJNR Am J Neuroradiol. 2024 09 09; 45(9):1214-1219.
-
Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease. JACC Heart Fail. 2024 08; 12(8):1328-1342.
-
Tolerability and efficacy of a reduced dose adenosine stress cardiac magnetic resonance protocol under general anesthesia in infants and children. Pediatr Radiol. 2023 10; 53(11):2188-2196.
-
Isosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial). Pediatr Cardiol. 2024 Oct; 45(7):1389-1397.
-
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA. 2023 04 11; 329(14):1170-1182.
-
Augmentation of perfusion with simultaneous vasodilator and inotropic agents in experimental acute middle cerebral artery occlusion: a pilot study. J Neurointerv Surg. 2023 Sep; 15(e1):e69-e75.
-
Relation of Myocardial Perfusion Reserve and Left Ventricular Ejection Fraction in Ischemic and Nonischemic Cardiomyopathy. Am J Cardiol. 2022 07 01; 174:143-150.
-
Quantitative Assessment of the Hemodynamic Effects of Intra-Arterial Nitroglycerin on Hepatocellular Carcinoma using Two-Dimensional Perfusion Angiography. J Vasc Interv Radiol. 2021 02; 32(2):198-203.